Mira Pharmaceuticals (MIRA) Non-cash Items (2024 - 2025)
Mira Pharmaceuticals (MIRA) posted Non-cash Items of $1.1 million for Q4 2025, down 68.63% sequentially from $3.4 million in Q3 2025, and up 689.2% YoY from $135200.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Non-cash Items (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 2 years of Non-cash Items data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Non-cash Items rose 689.2% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 689.2% YoY) and the FY2025 annual result came in at $1.1 million, down 54.57% from the prior year.
- Non-cash Items retreated to $1.1 million in Q4 2025 per MIRA's latest filing, from $3.4 million in the prior quarter.
- The five-year high for Non-cash Items was $4.0 million in Q2 2025, with the low at $135200.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 135,200.00 |
| Dec 31, 2024 | 135,200.00 |